FIELD: medicine.
SUBSTANCE: invention refers to biotechnology and gene engineering. What is described is a mouse having an incomplete N-terminal domain in IL-33 gene. The mouse is used as a model in vivo of inflammatory diseases for methods for selecting anti-inflammatory compounds and methods for assessing and optimising pharmacological properties of a certain anti-inflammatory compound.
EFFECT: invention can be used in pharmacology and medicine.
12 cl, 8 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANIMALS WITH HUMANIZED IL-4 AND IL-4Rα | 2015 |
|
RU2788523C2 |
| NEW FORM OF IL33, MUTATED FORMS OF IL33, ANTIBODIES, ANALYZES AND METHODS OF USING THEM | 2016 |
|
RU2736299C2 |
| ANIMALS WITH HUMANIZED IL-4 AND IL-4Rα | 2015 |
|
RU2703139C2 |
| ANTIBODIES AGAINST IL-33, COMPOSITIONS, METHODS AND THEIR APPLICATION | 2017 |
|
RU2740309C2 |
| DITRA MODELS IN NON-HUMAN ANIMALS AND THEIR USE | 2019 |
|
RU2804448C2 |
| NON-HUMAN ANIMALS WITH DISTURBANCE IN LOCUS C9ORF72 | 2016 |
|
RU2725737C2 |
| ANTIBODIES AGAINST HUMAN IL33R AND USE THEREOF | 2012 |
|
RU2597288C2 |
| HUMANISED IL-15 ANIMALS | 2014 |
|
RU2674910C2 |
| AGENT FOR PROPHYLAXIS AND/OR TREATMENT OF UNDESIRED INFLAMMATION ACTIVITY AND CANCER PROPHYLAXIS | 2000 |
|
RU2279282C2 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
